AI Article Synopsis
- Pancreatic Ductal Adeno Carcinoma (PDAC) is a highly lethal cancer, making early diagnosis crucial to improve patient outcomes.
- This study explores using magnetic levitation (MagLev) technology to detect PDAC by analyzing graphene oxide nanoparticles coated with proteins from blood samples of both PDAC and non-cancer patients.
- The method showed promising results, achieving 100% sensitivity, 80% specificity, and 90% overall accuracy, suggesting MagLev could be a valuable tool for early cancer detection.
Article Abstract
Pancreatic Ductal Adeno Carcinoma (PDAC) is one of the most lethal malignancies worldwide, and the development of sensitive and specific technologies for its early diagnosis is vital to reduce morbidity and mortality rates. In this proof-of-concept study, we demonstrate the diagnostic ability of magnetic levitation (MagLev) to detect PDAC by using levitation of graphene oxide (GO) nanoparticles (NPs) decorated by a biomolecular corona of human plasma proteins collected from PDAC and non-oncological patients (NOP). Levitation profiles of corona-coated GO NPs injected in a MagLev device filled with a paramagnetic solution of dysprosium(III) nitrate hydrate in water enables to distinguish PDAC patients from NOP with 80% specificity, 100% sensitivity, and global classification accuracy of 90%. Our findings indicate that Maglev could be a robust and instrumental tool for the early detection of PDAC and other cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533958 | PMC |
| http://dx.doi.org/10.3390/cancers13205155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!